Related by context. All words. (Click for frequent words.) 89 Announces Positive 82 Receives Positive 82 Announces Preliminary 81 Announces Successful Completion 81 Reveals Positive 81 Announces Initiation 80 Presents Positive 80 Announces Commencement 80 Net Loss Widens 79 Announces Termination 79 Net Loss Narrows 79 Successfully Completes 79 Announces Completion 79 Provides Update 78 Receives Notice 78 Receives Approval 78 Receives Milestone Payment 78 Provides Update Regarding 78 Announces Successful 78 More Than Doubles 78 Completes Successful 78 Provides Updates 78 Completes Enrollment 78 Updates Status 78 Announce Completion 78 Closes Acquisition 78 Finalizes Acquisition 78 Receives Patent 78 Q3 Loss Widens 78 Achieves Positive 78 Significantly Increases 78 Completes Initial 77 Closes Sale 77 Announces Receipt 77 Completes Patient Enrollment 77 Announces Revised 77 Positive Results 77 Submits Application 77 Provides Preliminary 77 Updates Shareholders 77 Secures Financing 77 Obtains Approval 77 Announces Presentation 77 Announces Filing 76 Announces Acquisition 76 Jumps Higher 76 Completes Purchase 76 Exercises Option 76 Q4 Loss Widens 76 Q4 Loss Narrows 76 Posts Strong 76 Q2 Loss Widens 76 Gets Approval 76 Announces Publication 76 Cites Positive 76 Finalizes Agreement 76 Q3 Loss Narrows 76 Announces Divestiture 76 Releases Third Quarter 76 Expects Higher 76 Reconfirms 76 Shareholders Approve 76 Shows Promise 76 Updates Guidance 76 Announces Closing 76 Announces Departure 76 Announces Signing 76 Completes Financing 76 Provides Operational Update 76 Announces Resignation 76 Announce Receipt 76 Provides Guidance 76 Completes Acquisition 75 Seeks Approval 75 Attains 75 Receives Notification 75 Announces Proposed 75 Reports Profitable 75 Announces Issuance 75 Posts Record 75 Closes Acquisition Of 75 Discontinues 75 Significant Increase 75 Finalizes 75 Receives Regulatory 75 Q2 Loss Narrows 75 Signs Agreements 75 Consummates 75 Commences 75 Posts Wider Loss 75 Announce License Agreement 75 Shareholders Approve Acquisition 75 Closes Previously Announced 75 Receives Favorable 75 Q1 Loss Narrows 75 Releases Second Quarter 75 Closes Financing 75 Q1 Loss Widens 75 Achieves Record 75 Files Shelf Registration Statement 75 Successfully Completed 75 Enters Into Agreement 75 Jointly Announce 75 Receives Orphan Drug Designation 75 Quadruples 75 Initiates Phase II 74 Enter Into 74 Completes Sale 74 Commences Phase 74 Enters Agreement 74 Sinks Lower 74 Posts Higher 74 Announces Addition 74 Announces Appointment 74 Acquires Assets 74 Announces Private Placement 74 Increases Ownership 74 Subsidiary Enters 74 Receives Conditional 74 Announces Non Brokered 74 Swings To 74 Obtains 74 Submits Biologics License Application 74 Acquires Controlling Interest 74 Strengthens Its 74 Loss Widens 74 Provides Clarification 74 Achieves Milestone 74 FDA Clears 74 Receives Conditional Approval 74 Nears Completion 74 Announce Licensing Agreement 74 Significantly Expands 74 Announces Formation 74 Announces Favorable 74 Shares Soar 74 Completes Merger 74 Announces Additions 74 Announces Effective Date 74 Shows Promising 74 Subsidiary Acquires 74 Maintains Strong 74 Announce Merger Agreement 74 Announces Stock Repurchase 74 Announces Expansion 74 Receives Approvable Letter 74 Closes Private Placement 74 Discloses 74 Reports Third Quarter 73 Aquires 73 Q2 Profit Rises 73 Sign Licensing Agreement 73 Enrolls First 73 Announces Postponement 73 Announces 73 Achieves Record Sales 73 Shareholders Approve Merger 73 Sign License Agreement 73 Initiates Clinical Trial 73 Announces FDA Clearance 73 Acquires Exclusive 73 Reports Second Quarter 73 Collaborators Present 73 Secures Funding 73 Confirms Significant 73 Licenses Novel 73 Presents Positive Preclinical 73 Receives FDA Clearance 73 Announces Licensing Agreement 73 Announces Expiration 73 Announces Shareholder Approval 73 Shares Surge 73 Completes Acquisitions 73 Completes Private Placement 73 Reports Receipt 73 Up Sharply 73 Completes 73 Present Preclinical Data 73 Enters Into 73 Sees Higher 73 Posts Solid 73 Sees Positive 73 Provides Updated 73 Presents Preclinical Data 73 Record Third Quarter 73 Signs Licensing Agreement 73 Signs Option Agreement 73 Significantly Improves 73 Reacquires 73 Increases Size 73 Acquire Assets 73 Loss Narrows 73 FDA Approves 73 Announces Expanded 73 Successfully Closes 73 Strengthens Balance Sheet 73 Announces Second Quarter 73 Progresses 73 Restructures 73 Appoints 73 Achieves Significant 73 Conference Call TRANSCRIPT 73 Q4 Profit Rises 73 Announces Availability 73 Files Patent Application 73 Nine Month 73 Annouces 73 Terminates 73 Subsidiary Signs 73 Sees Strong 72 Closes Second Tranche 72 Changes Name 72 Q1 Profit Rises 72 Monetizes 72 Confirms Receipt 72 Announces Cancellation 72 Demonstrates Positive 72 Announces Launch 72 Submits NDA 72 Announce Collaboration 72 Signs License Agreement 72 Significantly Reduces 72 Increases Stake 72 Completes Sale Of 72 Posts 4Q 72 Adopts Shareholder Rights 72 From Cont 72 Completes Previously Announced 72 Initiates Phase 72 Initiates 72 Q2 Profit Declines 72 Announces Refinancing 72 Completes Divestiture 72 Receives Unsolicited 72 Q3 Profit Rises 72 Successfully Complete 72 Begins Drilling 72 Wins Approval 72 Joins OTCQX 72 Files IND 72 Anounces 72 Completes Expansion 72 Stockholders Approve 72 Completes Merger With 72 Temporarily Suspends 72 Announces Upcoming 72 Awarded Patent 72 Reports Fiscal 72 Issues Guidance 72 Q3 Profit Surges 72 Posts Profit 72 Strengthens Position 72 Announces Proposed Acquisition 72 Announces Third Quarter 72 Repositions 72 Q1 Profit Declines 72 Announces Release Date 72 Initiates Phase III 72 Demonstrates Significant 72 Spins Out 72 Revises Guidance 72 Receives Order 72 Drug Candidate 72 Rated Speculative Buy 72 Initiates Dosing 72 Identifies Potential 72 Q4 Profit Surges 72 Terminates Contract 72 Earnings Decline 72 Reports Record 71 Confirms 71 Complete Merger 71 Executes Agreement 71 Bodes Well 71 Completes Purchase Of 71 Extends Offer 71 Q4 Profit Declines 71 Restates 71 Signs Definitive Agreement 71 Posts Narrower Loss 71 Q3 Profit Declines 71 Ink Deal 71 Receives Orphan Drug 71 Sees Significant 71 Commences Trading 71 widens Quick Facts 71 More Than Triples 71 Delivers Strong 71 Subsidiary Receives 71 Secures Additional 71 Explore Strategic Alternatives 71 Finalizes Purchase 71 Extends Tender Offer 71 Successfully Concludes 71 Submits 71 Acquirer Company 71 Earnings Rise 71 Profit Surges 71 Initiates Enrollment 71 Generates Record 71 Announce Collaboration Agreement 71 Announce Signing 71 4Q Loss Widens 71 Reports Significantly Improved 71 Announces Share Repurchase 71 Restate Financial 71 Announces Intention 71 Renegotiates 71 Study Confirms 71 Announces Early Termination 71 Beat Estimates 71 Announces Retirement 71 Receives Confirmation 71 Inks Deal With 71 Re Affirms 71 Drilling Underway 71 Completes Tender Offer 71 Delays Filing 71 Completes Transaction 71 FY# Loss Widens 71 Results Confirm 71 Disappoints 71 Board Authorizes 71 Posts Wider 71 Finalizes Sale 71 Posts Third Quarter 71 Announce Agreement 71 Initiates Clinical 71 Posts Quarterly 71 Receives NASDAQ 71 Further Strengthens 71 Begins Dosing 71 Receives Commitment 71 Successful Completion 71 Shares Plummet 71 Announces Definitive Agreement 71 Elevates 71 Regains Compliance With 71 Report Indicates 71 Boosts Stake 71 Continues Aggressive 71 Jointly Develop 71 Presents Preclinical 71 Q1 Adj 71 Enters Into Definitive Agreement 71 Announces Stockholder Approval 71 Initiates Clinical Trials 71 Shareholder Opinions 71 Lowers Guidance 71 Announces Dismissal 71 Acquires Remaining Interest 71 Grants Options 71 Mobilizes 71 Inks Pact 71 IIROC Resume 71 Moves Into 71 Posts Lower 71 Expand Collaboration 71 Guides Below 71 Announces Dosing 71 Receives Positive Results 70 Commences Operations 70 Issues Statement Regarding 70 IIROC Halt 70 Outperforms 70 Announce Merger 70 Voluntarily Withdraw 70 Expands Presence 70 Announces Normal Course 70 Continues Expansion 70 Stays Neutral 70 Successfully Completes Tender Offer 70 Extends Maturity 70 Extends Expiration Date 70 Settles Litigation 70 Amends Terms 70 Reduces Debt 70 Amends Agreement 70 Unveils Latest 70 Announces Intent 70 Announces Cash Dividend 70 Sells Shares 70 Zacks Analyst Blog Highlights 70 Study Demonstrates 70 Announces Enhancements 70 Recommences 70 Announce Availability 70 Shares Climb 70 Announces Restatement 70 Expands Into 70 Signs MOU 70 Drug Fails 70 Announce Settlement 70 Reports Fourth Quarter 70 Initiates Voluntary Recall 70 Announces Quarterly 70 Rises Quick Facts 70 Record Second Quarter 70 Revises Fourth Quarter 70 Sells Stake 70 Formalizes 70 Announces Organizational Changes 70 Reports Narrower 70 Nearly Triples 70 Receives Clearance 70 Receives 70 Univest Corporation Declares 70 Widens Quick Facts 70 News Unternehmensnachrichten 70 Plummets 70 1Q Loss Widens 70 Q1 Profit Surges 70 Announce Commencement 70 Expand Into 70 Clinical Trial Results 70 Announces Profitable 70 Terminates Agreement 70 Sets Record 70 Narrows Loss 70 Starts Drilling 70 Receives Certification 70 Announces License Agreement 70 Receives Fast Track 70 Continues Momentum 70 Achieves Profitability 70 CRWESelect CRWESelect.com Highlights 70 CybeRelease Decliners 70 Anticipates 70 Welcomes Analyst Initiation 70 Announce Initiation 70 Completes Patient Enrolment 70 Q2 Profit Surges 70 Announces Fiscal 70 TriCo Bancshares Announces 70 Edges Up 70 Better Than Expected 70 Announces Granting 70 Raises Guidance 70 Moves Forward 70 Board Unanimously Rejects 70 Declares Increased 70 Host Fourth Quarter 70 Snaps Up 70 Completes Drilling 70 Increases Quick Facts 70 Files Revised 70 Announce Exclusive 70 Reduces Risk 70 Regains Compliance 70 Provides Shareholder 70 Reorganizes 70 Finalises 70 Appoints Seasoned 70 Reaffirms Commitment 70 Announces Discontinuation 70 Summarizes 70 Preliminary Fourth Quarter 70 Momentum Continues 70 Signs Lease 70 PPD Declares 70 3Q Loss Narrows 70 Launches Enhanced 70 Announces Resumption 70 Completes Transition 70 Releases Latest 70 Gains Ground 70 Declares Increase 70 Previously Announced 70 Receives Approvals 70 Revenues Decline 70 Profits Soar 70 Expands Distribution 70 Report Examines 70 Launches Innovative 70 Stockholders Approve Merger 70 Posts Loss 70 Beats Forecasts 70 Gets Boost 70 Phase 2b Clinical Trial 70 Receives Tentative Approval 70 Schedules Second Quarter 70 Reaffirms Guidance 70 Reschedules 70 Signs Long Term 70 Assets Acquirer Company 70 Beefs Up 70 4Q Loss Narrows 70 Expands Portfolio 70 Completes Integration 70 Acquires 70 VIVUS Announces 70 Shareholders Approve Sale 70 Spins Off 70 Q4 Profit Plunges 70 Signs Letter 70 Validates 70 Fortifies 70 Receives Prestigious 70 Files Registration Statement 70 Signs Agreement 70 Forges Ahead 70 Announces Sponsorship 70 Stock Soars 69 Outshines 69 narrows Quick Facts 69 Above Estimates 69 Profit Doubles 69 Regains Full 69 Receives Favorable Ruling 69 Record Fourth Quarter 69 Resumes Drilling 69 Reports Sharply Higher 69 Obtains License 69 Misses Estimate 69 Exceeds Expectations 69 Completes Restructuring 69 Announces Participation 69 Wraps Up 69 Announces Record Date 69 Beats Estimates 69 Diversifies 69 Announces Dividend 69 Signs LOI 69 Completes Installation 69 Enters Into Letter 69 Completes Refinancing 69 Up Slightly 69 Introduces Next Generation 69 Raises Bid 69 Sign Definitive Agreement 69 Guides Above 69 Flamel Technologies Announces 69 Posts 2Q 69 BayStreet.ca Research Alert 69 Ups Stake 69 BioSante Pharmaceuticals Announces 69 Announces Operational Update 69 Files Preliminary Prospectus 69 Declines Quick Facts 69 Expand Relationship 69 Commences Drilling 69 Bulks Up 69 Helps Reduce 69 Furthers 69 Files Restated 69 Accelerates 69 Ramps Up 69 FY# Loss Narrows 69 Introduces Innovative 69 Announce Second Quarter 69 FDA Okays 69 Completes Conversion 69 1st Quarter Results 69 Commences Tender Offer 69 Extends Contract 69 Therapeutic Competitors Companies 69 Launches Next Generation 69 Announces Immediate Availability 69 Stockholders Approve Acquisition 69 Retains Investor Relations 69 Reaches Milestone 69 Second Consecutive 69 Successfully Tests 69 Announces Adjournment 69 Announces Consummation 69 Moves Towards 69 Study Indicates 69 Engages 69 Propels 69 Sweetens Bid 69 Host Third Quarter 69 More Than Doubled 69 3Q Loss Widens 69 Schedules Third Quarter 69 Rebrands 69 Drilling Intersects 69 Completes Due Diligence 69 Study Identifies 69 Completes Dosing 69 Officially Launches 69 Announcement Regarding 69 Gears Up 69 Receive Milestone Payment 69 Submits IND 69 CFO Resigns 69 Enters Into Strategic 69 Dramatically Increases 69 Announce Definitive Agreement 69 Emerges From 69 Holds Annual Meeting 69 Takes Stake 69 Sets Second Quarter 69 Winning Streak Continues 69 Recieves 69 Posts Narrower 69 Host Second Quarter 69 Pinnacle Digest Looking 69 Higher Than Expected 69 Schedules Fourth Quarter 69 Retracts 69 Strengthens Leadership 69 Patient Enrollment 69 Revenues Increase 69 Profits Rise 69 Bolsters 69 Clarifies Status 69 Acquire Controlling Interest 69 Positions Itself 69 Ranked Number 69 Earnings Postmortem 69 Develop Novel 69 Broadens Its 69 Third Consecutive 69 Expands Capabilities 69 Enters Joint Venture 69 Beats Views 69 Commercializes 69 Achieves Highest 69 Divests 69 Lupus Drug 69 Moves Closer 69 Declares Second Quarter 69 Realigns 69 Receives Positive Opinion 69 Announces Underwriters Exercise 69 Beats Expectations 69 Extends Reach 69 Statement Regarding 69 Downtrend Spotted 69 Strikes Deal 69 Fourth Consecutive 69 Shares Plunge 69 Concludes Successful 69 Closes Buyout 69 Improves Survival 69 Regains 69 Attracts Attention 69 Announces Bought Deal 69 Reports Third Consecutive 69 Reinforces 69 Reach Agreement 68 Gets FDA Clearance 68 Halts Production 68 Approve Merger 68 Successfully Completes Acquisition 68 Enters Negotiations 68 Reschedules Fourth Quarter 68 Reactivates 68 Announce Third Quarter 68 Commence Drilling 68 Extends Deadline 68 Directors Authorizes 68 Guides Inline 68 Cuts FY# 68 Opens Door 68 Little Changed 68 Profit Soars 68 Bearish Speculation 68 Announce Early Termination 68 Widens 68 Raises Stake 68 Moves Ahead 68 Appoints Experienced 68 Narrows Guidance 68 Secures 68 Announces Fourth Quarter 68 Profit Increases 68 Expands 68 Renews Agreement 68 SWOT Analysis Aarkstore Enterprise 68 Signs Pact 68 Wins Contract 68 Declares Fourth Quarter 68 Substantially Increases 68 Losses Narrow 68 Signs Contract 68 Ups Bid 68 Holds Steady 68 Delivers Solid 68 Q3 Profit Soars 68 Completes Recapitalization 68 Exceeds Estimates 68 Makes Debut 68 Extends Losses 68 Announce Partnership 68 Receives SFDA Approval 68 Revolutionizes 68 Reaches Agreement 68 Plunges 68 Announces Dates 68 Receives Complete Response 68 Bounces Back 68 Settle Patent Litigation 68 Phase III Clinical Trial 68 Sees Continued 68 Hold Fourth Quarter 68 Meets Primary Endpoint 68 Unveils Innovative 68 Cuts Costs 68 Bullish Speculation 68 Receives Notice From 68 Signs Definitive 68 Phase IIb Trial 68 Shares Tumble 68 Receives Approval From 68 Inks Deal 68 Announces Webcast 68 Redeems 68 Settle Patent Dispute 68 Receives Recognition 68 PROFILE CO 68 Announces Timing 68 L.P. Announces 68 Introduces Enhanced 68 Sets Date 68 Relocates 68 Lowest Level 68 Profitable Quarter 68 Sees Increase 68 Makes Bid 68 Enters Final 68 Heightens 68 Successfully Completes Phase 68 Announces Redemption 68 Commences Exploration 68 Profit Declines 68 Announce Joint Venture 68 Helps Boost 68 Has Received 68 Acquires Remaining 68 Sells Portion 68 1Q Profit Falls 68 Files Amended 68 Publishes 68 Down Slightly 68 Receives Shareholder Approval 68 Inc. Nasdaq OXGN 68 Named Fastest Growing 68 Affirms Commitment 68 Releases Next Generation 68 Report Initiates Independent 68 Deepens 68 Gets Nod 68 Files Patent 68 Slightly Lower 68 Submits Supplemental 68 Pave Way 68 Expands Reach 68 Sets Fourth Quarter 68 Completes Asset 68 Takes Steps 68 Secures Long Term 68 1st Writethru 68 Satisfies 68 Announces Pricing 68 Increases Risk 68 Below Estimates 68 Calls Purchased 68 Proudly Announces 68 Trend Continues Down 68 Signs Joint Venture 68 Doubles Capacity 68 Achieves Primary Endpoint 68 Revises Third Quarter 68 Helps Lift 68 Earns Milestone Payment 68 Bullish Average Crossover 68 Files Annual Report 68 Provides Detailed 68 Resubmits 68 Closes Merger 68 Shareholders Elect 68 Celebrates Successful 68 Reaches Record 68 Amplifies 68 Commences Production 68 Breaks Through 68 Buys Stake 68 Acquires Majority 68 Release Second Quarter 68 Hold Third Quarter 68 Nearing Completion 68 Loses Ground 68 Spectrum Pharmaceuticals Announces 68 Results Exceed Expectations 68 Files Shelf Registration 68 Patent Issued 68 Extends Collaboration 68 Preliminary Second Quarter 68 Announces Delisting 68 Commences Phase III 68 Expansion Continues 68 Rise Sharply 68 Subsidiary Completes 68 Commence Trading 68 Falls Sharply 68 Streamlines Operations 68 Revises Q4 68 Webcast Presentations 68 Earnings Cheat Sheet 68 Demonstrates Long Term 68 Record Highs 68 Shows Signs 68 Receives Funding 68 Daytradersdigest.com 68 Joins 68 Announce Formation 68 Trial Evaluating 68 Bearish MACD 68 Remains Neutral 68 Issues Clarification 68 Impresses 68 Misses Estimates 68 Agreement Reached 68 Sees Surge 68 Serves Up 68 Keeps Climbing 68 Reclassifies 68 Extends Term 68 Preliminary Third Quarter 68 Increases Quarterly Cash Dividend 68 Granted Orphan Drug 68 Options Activity 68 Achieves Unprecedented 68 Crowflight Announces 68 Announces Tentative Approval 68 FFO Rises 68 Restructures Debt 68 Results Indicate 67 Could Trigger 67 Amends Credit 67 Webcast Second Quarter 67 Announce Successful Completion 67 Well Positioned 67 Reaffirms Outlook 67 FDA Accepts 67 Sees Robust 67 Beat Expectations 67 Rejoins 67 Awarded Patents 67 Commences Drill Program 67 Expands Scope 67 Announces Affiliation 67 Expands Coverage 67 Edges Higher 67 Completes Buyout 67 Release Fourth Quarter 67 IrelandRESEARCH AND MARKETS 67 Options Trader Alert 67 Reveals 67 Forecast Quick Facts 67 Movers Roundup 67 Declares Dividend 67 Pending Acquisition 67 Commence Phase 67 Attracting Bullish Investors 67 Introduces Revolutionary 67 Sees Wider 67 Accelerates Growth 67 Sees 2Q 67 Looks Ahead 67 AllPennyStocks.com Spotlights 67 Gives Boost 67 Reacquire 67 Signs Exclusive 67 Outlines Strategy 67 2nd Quarter Results 67 Declares Cash Dividend 67 Discovers 67 Exploring Strategic Alternatives 67 Post Earnings Checkup 67 Second Quarter Profit Rises 67 Skymark Research Initiates Independent 67 Completes Second Tranche 67 Reports Preclinical Data 67 Extends Relationship 67 Regains NASDAQ 67 www.otc advisors.com names 67 Doubles Size 67 Launches Website 67 Launches 67 Nominates 67 Refocuses 67 Acquire Stake 67 Projected Release Date 67 Renames 67 Rises Sharply 67 Q2 Profit Soars 67 Beats Analyst 67 Celebrates Opening 67 Files NI #-# 67 Profits Jump 67 Hits Milestone 67 Identifies Significant 67 Announces Tender Offer 67 Evaluate Strategic Alternatives 67 Immunomedics Announces 67 1Q Loss Narrows 67 Discuss Third Quarter 67 Pursues 67 Provides Comprehensive 67 Initiate Phase III 67 Buys Majority Stake 67 Announce Expiration 67 Breaks Out 67 Announces Debt Settlement 67 Profit Climbs 67 Gobbles Up 67 4Q Loss 67 Penetrates 67 Puts Purchased 67 Clears Path 67 Sharply Higher 67 Reports Assay Results 67 Finalizes Sale Of 67 Acquires Majority Stake 67 Rejects Unsolicited 67 Announces Repurchase 67 Eighth Consecutive 67 Uptrend Spotted 67 Introduces Breakthrough 67 Declares Regular Quarterly 67 Receives Prestigious Award 67 Sets Dates 67 Q2 Profit Drops 67 Enters Oversold Territory 67 Phase IIb Clinical Trial 67 Taps Into 67 Sees 4Q 67 Subsidiary Awarded 67 Unveils Next Generation 67 Misses Expectations 67 Sweetens 67 Bullish Engulfing Pattern 67 Shareholders Approve Merger Agreement 67 Forms Strategic 67 Paves Way 67 Alert Technicals Showing Bearish 67 Obtains Exclusive License 67 Raises Funds 67 Begins Shipping 67 Commences Initial 67 Arranges Financing 67 Submits Response 67 Withdraws 67 Single Dose 67 Fifth Consecutive 67 Expands Capacity 67 Ups Guidance 67 Updates Outlooks 67 Wins Prestigious 67 Bullish Technical Alert 67 Enters Into License Agreement 67 Mails Offer 67 Lowers Outlook 67 Scoops Up 67 Concludes Acquisition 67 Increases Capacity 67 Has Commenced 67 Unveils Expanded 67 Enters Into Exclusive 67 Identifies Key 67 Webcast Third Quarter 67 Profit Triples 67 Release Third Quarter 67 Q4 Profit Soars 67 Elects 67 Undertakes 67 Raises Outlook 67 Schedules Release 67 Remains Committed 67 Remains Positive 67 Activity Alert 67 Commercialize 67 Secures Contract 67 Relaunches 67 Inc. OTCBB MNDP 67 Profit Slips 67 Profit Drops 67 Announces Voluntary Recall 67 Repays 67 Confirms Commitment 67 &Amp; 67 Lower Than Expected 67 Posts Fourth Quarter 67 Posts 1Q 67 Sets Sights 67 Reaffirms Full 67 Phase III Trial 67 Reminds Shareholders 67 3rd Quarter Results 67 Shifts Focus 67 Novartis Novo Nordisk 67 Enters Strategic 67 Significantly Improved 67 Slightly Higher 67 CRWEWallstreet.com Stock Report 67 Makes Strides 67 3Q Profit Up